0001209191-22-056427.txt : 20221110 0001209191-22-056427.hdr.sgml : 20221110 20221110171323 ACCESSION NUMBER: 0001209191-22-056427 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20221108 FILED AS OF DATE: 20221110 DATE AS OF CHANGE: 20221110 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Patel Sanjiv CENTRAL INDEX KEY: 0001816210 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39385 FILM NUMBER: 221378536 MAIL ADDRESS: STREET 1: C/O RELAY THERAPEUTICS, INC. STREET 2: 399 BINNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Relay Therapeutics, Inc. CENTRAL INDEX KEY: 0001812364 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 399 BINNEY STREET STREET 2: 2ND FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 617-370-8837 MAIL ADDRESS: STREET 1: 399 BINNEY STREET STREET 2: 2ND FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02139 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2022-11-08 0 0001812364 Relay Therapeutics, Inc. RLAY 0001816210 Patel Sanjiv C/O RELAY THERAPEUTICS, INC. 399 BINNEY STREET, 2ND FLOOR CAMBRIDGE MA 02139 1 1 0 0 President and CEO Common Stock 2022-11-08 4 M 0 14000 4.12 A 268554 D Common Stock 2022-11-08 4 S 0 14000 20.18 D 254554 D Common Stock 2022-11-10 4 M 0 18175 4.12 A 272729 D Common Stock 2022-11-10 4 S 0 18175 20.00 D 254554 D Common Stock 2022-11-10 4 M 0 9825 5.04 A 264379 D Common Stock 2022-11-10 4 S 0 9825 20.00 D 254554 D Common Stock 674548 I By The Patel Family Irrevocable Trust of 2019 Common Stock 432801 I By The SSP Irrevocable Trust of 2020 Stock Option (Right to Buy) 4.12 2022-11-08 4 M 0 14000 0.00 D 2028-03-22 Common Stock 14000 18175 D Stock Option (Right to Buy) 4.12 2022-11-10 4 M 0 18175 0.00 D 2028-03-22 Common Stock 18175 0 D Stock Option (Right to Buy) 5.04 2022-11-10 4 M 0 9825 0.00 D 2029-04-22 Common Stock 9825 694779 D The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on July 22, 2022. This transaction was executed in multiple trades at prices ranging from $20.00 to $20.43. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. These shares are held in irrevocable trusts for the benefit of the reporting person's family members. An independent trustee is trustee of the trusts. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. The shares underlying this option shall vest in sixteen (16) equal quarterly installments after March 23, 2018, subject to the reporting person's continued employment through each applicable vesting date. The shares underlying this option shall vest in sixteen (16) equal quarterly installments after April 23, 2019, subject to the reporting person's continued employment through each applicable vesting date. /s/ Brian Adams, as Attorney-in-Fact 2022-11-10